Drawing upon our extensive experience in developing therapeutics for chronic liver diseases and viral infections, we are building a pipeline of potentially best-in-class drug candidates. These drug candidates target multiple clinically validated mechanisms of action and are designed to become transformative treatment options MASH and viral diseases.


*Our Covid-19 protease inhibitor programs are partly funded (>$12M USD awarded) by the NIH and NIAID’s AViDD Centers for Pathogens of Pandemic Concern program through the MAVDA consortium and our recently awarded NIAID Contract.

AASLD = American Association for the Study of Liver Diseases; APASL = Asian Pacific Association for the Study of the Liver; CAM-E = capsid assembly modulator (empty); CHB = chronic hepatitis B; Covid-19 = coronavirus disease of 2019 (SARS-CoV-2); EASL = European Association for the Study of the Liver; HV = healthy volunteers; MoA = mechanism of action; MRI-PDFF = Magnetic Resonance Imaging Proton Density Fat Fraction; MASH = metabolic dysfunction associated steatohepatitis; ; THR-β = thyroid hormone receptor beta.

All timelines are approximate and subject to change based on enrollment and operational considerations. Presentations at conferences are subject to abstract approvals.